Radafaxin

Structural formula
General
Non-proprietary name	Radafaxin
other names	(+) - (2 S , 3 S ) -2- (3-chlorophenyl) -3,5,5-trimethylmorpholin-2-ol
Molecular formula	C 13 H 18 ClNO 2
External identifiers / databases
CAS number 192374-14-4 106083-71-0 (hydrochloride) PubChem 9795056 DrugBank DB11790 Wikidata Q1485208
Drug information
Drug class	antidepressant
properties
Molar mass	255.74 g · mol -1
safety instructions
GHS labeling of hazardous substances Caution H and P phrases H: 319 P: ?
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Radafaxin is a selective norepinephrine dopamine reuptake inhibitor ( NDRI ) originally developed by GlaxoSmithKline for the treatment of Restless Legs Syndrome . However, development was stopped in 2006 due to poor test results.

Chemistry and stereoisomerism

Radafaxine is enantiomerically pure and is a metabolite of the drug bupropion ( racemate ). Radafaxin's effects in humans are similar to those of bupropion.

The hydrochloride is used in finished medicinal products .

Pharmacological properties

Radafaxine blocks the reuptake of dopamine with 70% efficiency of bupropion and norepinephrine with 392% efficiency.

Radafaxin's effectiveness in treating depression , obesity, and neuropathic pain has been studied in clinical studies . It turned out that radafaxine, in contrast to bupropion, is better suited for the treatment of pain and fatigue, which is probably related to the stronger inhibition of the reuptake of the messenger substance norepinephrine.

Similar to bupropion, radafaxine is said to have only a low abuse potential.

Individual evidence

1. ↑ There is not yet a harmonized classification for this substance . A labeling of [No public or meaningful name is available] in the Classification and Labeling Inventory of the European Chemicals Agency (ECHA), accessed on July 11, 2020, is reproduced from a self-classification by the distributor .
2. ^ Restless Legs Syndrome: First Approval ( Memento of December 19, 2006 in the Internet Archive ).
3. ↑ Reviews Novel Therapeutics For CNS Disorders And Confirms Strong Pipeline Momentum - News, Search Jobs, Events ( Memento of the original from September 28, 2007 in the Internet Archive ) Info: The archive link was automatically inserted and not yet checked. Please check the original and archive link according to the instructions and then remove this notice. 
4. ↑ Independent.co.uk: GSK breakthrough on bird flu vaccine ( Memento of the original from October 1, 2007 in the Internet Archive ) Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. . 
5. ↑ MeSH Radafaxin .
6. ^ GlaxoSmithKline Reviews Novel Therapeutics for CNS Disorders and Confirms Strong Pipeline Momentum ( Memento of September 29, 2007 in the Internet Archive ).
7. ↑ External identifiers or database links for Radafaxin hydrochloride : CAS number: 106083-71-0, EC number: 689-425-6, ECHA InfoCard: 100.216.309 , PubChem : 9838996 , ChemSpider : 8014715 , Wikidata : Q27289464 .
8. ↑ H. Xu, KK Loboz, AS Gross, AJ McLachlan: Stereoselective analysis of hydroxybupropion and application to drug interaction studies. In: Chirality . 19, 2007, pp. 163-170. PMID 17167747 .
9. ↑ ML Bondarev, TS Bondareva, R. Young, RA Glennon: Behavioral and biochemical investigations of bupropion metabolites. In: Eur J Pharmacol . 474, 2003, pp. 85-93. PMID 12909199 .
10. ^ GlaxoSmithKline, Daniel Burch: Neurosciences Development Portfolio ( Memento of September 28, 2007 in the Internet Archive ).
11. ↑ Radafaxine .

This article is about a health issue. It is not used for self-diagnosis and does not replace a diagnosis by a doctor. Please note the information on health issues !